Last updated: November 8, 2026
Clinoril is the former brand name for sulindac, a nonsteroidal anti-inflammatory drug marketed by Merck. Its commercial trajectory is mature and largely complete as a branded-product story. Sulindac is now a low-cost generic medicine with limited commercial differentiation, no meaningful branded pricing power, and no publicly reported standalone revenue stream. Market value is tied to generic prescription volume, wholesaler contracts, reimbursement, and manufacturing economics rather than patent protection.
What is Clinil or Clinoril and how is sulindac used?
Clinoril contains sulindac, an indene acetic acid derivative and prodrug that is converted in vivo to an active sulfide metabolite. The FDA-approved label identifies sulindac for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute painful shoulder, and acute gouty arthritis in adults. [1]
| Attribute |
Clinoril and sulindac |
| Brand |
Clinoril |
| Active ingredient |
Sulindac |
| Drug class |
Nonsteroidal anti-inflammatory drug |
| Original innovator |
Merck & Co. |
| Dosage form |
Oral tablets |
| Historical strengths |
150 mg and 200 mg |
| FDA status |
Approved small-molecule prescription drug |
| Current commercial model |
Generic sulindac |
| Primary market |
U.S. and international generic markets |
| Current differentiation |
Limited |
Sulindac is administered orally and is generally dosed at 150 mg or 200 mg twice daily, subject to indication and patient factors. The label carries class warnings involving gastrointestinal bleeding, cardiovascular events, renal toxicity, hypertension, and adverse reactions associated with nonsteroidal anti-inflammatory drugs. [1]
When did Clinoril lose exclusivity?
Clinoril lost commercial exclusivity decades ago. The product is no longer protected by a commercially meaningful patent estate, and sulindac competes as a mature generic active pharmaceutical ingredient.
The original small-molecule composition and product patents would have expired no later than the late 1990s or early 2000s, depending on the relevant patent family, patent-term adjustments, and market-specific extensions. Because the drug was introduced in the 1970s, its principal composition-of-matter protection could not support exclusivity in the current market.
What is the FDA Orange Book status of Clinoril?
The FDA Orange Book is the principal U.S. source for approved drug products, therapeutic-equivalence evaluations, and patent or exclusivity listings submitted by sponsors. Current commercial sulindac products are generic versions rather than a protected, actively marketed Clinoril brand. [2]
The relevant Orange Book commercial characteristics are:
| Issue |
Status |
| Active Clinoril brand franchise |
No meaningful current franchise |
| Generic availability |
Yes |
| New-drug exclusivity |
Expired |
| Patent-based brand exclusivity |
Expired |
| Paragraph IV activity |
Not a current commercial driver |
| Authorized generic strategy |
Not material |
| FDA regulatory pathway |
ANDA-based generic competition |
A historical Orange Book entry does not create current commercial protection. Any old listing associated with Clinoril must be evaluated against patent expiration, product discontinuation, FDA status, and the absence of a current branded launch strategy.
How many patents cover sulindac and Clinoril?
The important distinction is between historical patent coverage and enforceable market protection. Sulindac was discovered and commercialized many years ago. Its core composition patent, original formulation protection, and early method-of-use rights are not a current barrier to generic entry.
Potential historical patent categories included:
- Sulindac composition-of-matter patents.
- Manufacturing and chemical-process patents.
- Tablet formulation patents.
- Therapeutic-use claims for inflammatory and musculoskeletal conditions.
- Salt, polymorph, or stability claims, if granted in particular jurisdictions.
These rights do not produce a current U.S. monopoly. Generic manufacturers can generally enter by demonstrating pharmaceutical equivalence and bioequivalence through the abbreviated new drug application pathway, assuming compliance with FDA quality and manufacturing requirements. [2,3]
How strong is the Clinoril patent estate?
The current patent estate is commercially weak. Core patent expiration removes the main source of value, while broad indications such as osteoarthritis and rheumatoid arthritis are difficult to protect through late-stage method-of-use rights because they are longstanding clinical uses.
| Patent-estate factor |
Commercial assessment |
| Composition protection |
Expired |
| Basic tablet protection |
Expired or commercially irrelevant |
| Broad anti-inflammatory indications |
Expired or difficult to enforce |
| Manufacturing know-how |
Potentially useful, but not exclusivity-creating |
| Formulation patents |
No known current blockbuster-grade barrier |
| Pediatric exclusivity |
Not commercially relevant |
| Orphan-drug protection |
Not applicable |
| Biosimilar protection |
Not applicable |
Manufacturing know-how can still affect supplier economics, impurity control, process yield, and regulatory compliance. It does not prevent other qualified manufacturers from producing sulindac.
What is the current market position of sulindac?
Sulindac occupies a mature, low-growth segment of the prescription NSAID market. It competes with generic naproxen, ibuprofen, diclofenac, meloxicam, celecoxib, etodolac, indomethacin, and other anti-inflammatory medicines.
Its competitive position is constrained by:
- Low generic pricing.
- Extensive therapeutic substitution.
- Availability of over-the-counter NSAIDs for some indications.
- Physician familiarity with alternative NSAIDs.
- Gastrointestinal, cardiovascular, renal, and hepatic safety considerations.
- Limited current promotional spending.
- Lack of differentiated delivery technology.
- Absence of meaningful brand equity among younger prescribers.
Sulindac retains clinical relevance in certain patients and indications, but it is not a high-growth product. Prescription demand is generally driven by individual physician preference, formulary placement, prior treatment history, and patient tolerability.
How does sulindac compare with competing NSAIDs?
| Drug |
Market status |
Relative commercial position |
| Sulindac |
Generic |
Mature, low-priced, niche-to-established volume |
| Naproxen |
Generic and OTC |
Broad use and strong consumer recognition |
| Ibuprofen |
Generic and OTC |
Very broad volume, intense price competition |
| Diclofenac |
Generic |
Strong international use, multiple dosage forms |
| Meloxicam |
Generic |
Common chronic-use alternative |
| Celecoxib |
Generic |
Selective COX-2 positioning and higher historical pricing |
| Indomethacin |
Generic |
Established but limited by tolerability concerns |
| Etodolac |
Generic |
Smaller mature market |
| Aspirin |
Generic and OTC |
Broad historical use, different clinical positioning |
Sulindac’s potential advantage is historical familiarity and continued availability in prescription tablet form. Its disadvantages are the absence of patent-based differentiation and the availability of lower-cost or more familiar alternatives.
What is the financial trajectory for Clinoril and sulindac?
The financial trajectory has four stages:
| Period |
Commercial phase |
Financial characteristics |
| 1970s to 1980s |
Branded launch and expansion |
Innovator pricing, sales-force support, patent value |
| 1990s |
Mature branded product |
Slower growth and increasing substitution risk |
| Post-exclusivity period |
Generic entry |
Rapid price compression and volume fragmentation |
| Current market |
Mature generic |
Low unit prices, limited promotion, supplier-driven economics |
Merck does not report current standalone Clinoril revenue as a material branded product. Public company filings generally aggregate mature products into broader pharmaceutical categories, and sulindac sales are not separately identified in current Merck financial reporting. [4]
The product’s financial value has therefore shifted from brand revenue to generic supply economics. A generic manufacturer may earn revenue through:
- High-volume institutional and retail contracts.
- Stable prescriptions in selected therapeutic niches.
- Efficient active-ingredient sourcing.
- Reliable FDA-compliant manufacturing.
- Low-cost packaging and distribution.
- Contract manufacturing or private-label supply.
No reliable public basis exists for assigning a current standalone global revenue figure to Clinoril itself. The relevant financial exposure is the aggregate generic sulindac market, which is fragmented across manufacturers and distribution channels.
Which companies are challenging Clinoril exclusivity?
Clinoril is not currently experiencing a conventional branded exclusivity challenge. The relevant challengers are generic manufacturers and distributors supplying sulindac tablets.
Historical U.S. generic competition has included manufacturers that participate in the broader generic prescription market. The commercial identity of individual sulindac suppliers can change through product discontinuations, acquisitions, portfolio rationalization, and wholesaler substitution.
This market structure differs from a modern protected drug facing a Paragraph IV challenge. A Paragraph IV certification is relevant when an ANDA applicant alleges that a listed patent is invalid, unenforceable, or not infringed. [3] For sulindac, the principal competitive event occurred when historical exclusivity expired and generic manufacturers entered. There is no current high-value Paragraph IV litigation dynamic comparable to a recently launched branded medicine.
What generic entry risks exist for sulindac?
Generic entry risk is effectively realized rather than prospective. The product already operates in a generic market.
The principal risks for a sulindac supplier are commercial:
- Price erosion from additional manufacturers.
- FDA warning letters or manufacturing deficiencies.
- Active-ingredient supply disruption.
- Contract loss to larger generic suppliers.
- Product discontinuation caused by low margins.
- Reimbursement changes.
- Demand migration to naproxen, meloxicam, or celecoxib.
- Pharmacovigilance concerns affecting prescribing.
The main barrier is not intellectual property. It is the ability to maintain a compliant, economical, and reliable supply chain.
Are there formulation patents or method-of-use patents protecting Clinoril?
No currently meaningful formulation or method-of-use protection is evident from the mature commercial status of sulindac. The historical product was an immediate-release oral tablet, a dosage form that generally offers limited opportunity for durable secondary patent protection.
A later entrant could theoretically pursue:
- Modified-release sulindac.
- Gastroprotective combinations.
- Topical delivery.
- Fixed-dose combinations.
- New salts or crystalline forms.
- Narrow method-of-use claims.
- Abuse-deterrent or targeted delivery systems.
Such a strategy would require clinical, regulatory, and reimbursement differentiation. It would not restore the original Clinoril franchise automatically. Any new formulation would need independent FDA approval and enforceable intellectual-property rights.
What is the FDA regulatory status of sulindac?
Sulindac remains an FDA-approved prescription NSAID in generic tablet form. Approval is supported by the established-drug framework and ANDA submissions from generic manufacturers. FDA labeling continues to address NSAID class risks, including cardiovascular and gastrointestinal events. [1,2]
Sulindac is not a biologic. Biosimilar competition does not apply. The relevant regulatory pathway is generic-drug substitution, not the 351(k) biosimilar pathway under the Public Health Service Act.
What patent litigation and settlement agreements affect Clinoril?
No current high-value patent litigation or settlement structure materially affects the commercial outlook for Clinoril. Its market is too mature for the original brand patent estate to function as a significant litigation asset.
Historical litigation, if any, would be relevant primarily to the timing of generic entry and the scope of earlier patents. It does not change the present conclusion: sulindac is commercially exposed to generic competition and does not have a current blockbuster-style patent barrier.
What geographic markets remain commercially relevant?
Sulindac has international commercial availability, but product status varies by country. Key differences include:
- National approval and reimbursement rules.
- Local generic substitution policies.
- Availability of brand-name Clinoril or successor brands.
- National patent-term rules.
- Local manufacturing requirements.
- Prescription volume and physician familiarity.
- Distribution concentration.
The United States is a mature generic market. International markets may retain branded or semi-branded sulindac products, but local brands do not recreate global exclusivity. Patent rights are territorial, and expired U.S. protection does not determine the legal status of every foreign product.
What is the outlook for Clinoril and sulindac?
The outlook is stable but economically limited. Sulindac is likely to remain available while demand supports generic production, but it has little basis for substantial price growth or branded revival.
A manufacturer could improve economics through dependable supply, hospital contracting, or a differentiated formulation. The standard tablet market, however, is unlikely to generate material innovation-led growth. Any investment thesis should focus on manufacturing efficiency, portfolio fit, supply reliability, and regulatory execution rather than patent appreciation.
Key Takeaways
- Clinoril is the former Merck brand for sulindac.
- Sulindac is an established generic NSAID with expired core exclusivity.
- Current commercial value comes from generic volume and manufacturing efficiency.
- Clinoril has no meaningful active branded franchise or current patent moat.
- Paragraph IV litigation is not a major current market driver.
- Biosimilar risk does not apply because sulindac is a small-molecule drug.
- Formulation and method-of-use patents do not currently create material market protection.
- Revenue is not publicly reported as a standalone Clinoril line item.
- Competition comes from generic sulindac suppliers and substitute NSAIDs.
- The commercial outlook is mature, price-sensitive, and stable rather than growth-oriented.
FAQs About Clinoril and Sulindac
Is Clinoril still sold under the original brand name?
Clinoril is not a meaningful current branded franchise in the U.S. Sulindac is primarily supplied as a generic prescription tablet.
Is sulindac stronger than ibuprofen?
Clinical effectiveness varies by indication, dose, patient response, and tolerability. Sulindac does not have a general market-wide potency advantage that supports premium pricing over ibuprofen.
Can a generic manufacturer launch sulindac without a license from Merck?
A generic manufacturer does not need a current license from Merck to sell sulindac when applicable patents and exclusivities have expired. It must obtain FDA approval and satisfy manufacturing requirements.
Does sulindac have a biosimilar competitor?
No. Sulindac is a chemically synthesized small molecule, so competition occurs through generic-drug approval rather than biosimilar approval.
Could a new extended-release sulindac product recreate Clinoril exclusivity?
A new extended-release product could potentially receive separate patent and FDA protection if it met patentability and regulatory requirements. That protection would apply to the new formulation, not automatically to standard sulindac tablets.
References
- U.S. Food and Drug Administration. (n.d.). Sulindac prescribing information. FDA-approved labeling.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and patent certifications.
- Merck & Co., Inc. (n.d.). Annual reports and filings. U.S. Securities and Exchange Commission.
